BRF1 Antibody

What is BRF1 and what are its molecular functions in cellular processes?

BRF1 (TFIIB-related factor 1) is a general activator of RNA polymerase III that utilizes different TFIIIB complexes at structurally distinct promoters. It serves critical functions in transcriptional regulation:

• Isoform 1 is specifically involved in the transcription of tRNA, adenovirus VA1, 7SL and 5S RNA

• Isoform 2 is required for transcription of the U6 promoter

At the molecular level, BRF1 functions as part of the TFIIIB complex, which includes the TATA-binding protein (TBP) and TFIIIB. This complex is recruited by TFIIIC2 to promoter elements and plays a key role in regulating RNA polymerase III-mediated transcription . The regulation of BRF1 expression is important for controlling cell growth and proliferation, as cells must produce high levels of Pol III-transcribed RNA to maintain rapid growth.

Recent research has shown that BRF1 also has additional functions beyond its classical role in transcription. It operates downstream of FGF/Erk MAP kinase signaling to regulate pluripotency and cell fate decisions in embryonic stem cells, and it can bind AU-rich sequences in many pluripotency-associated mRNAs to regulate their localization and abundance .

What applications are BRF1 antibodies validated for, and what are their performance characteristics?

BRF1 antibodies have been validated for multiple research applications with specific performance parameters:

Performance characteristics vary between antibodies:

• Most antibodies show a predicted band size of 74 kDa, though additional bands at 140 kDa and 200 kDa have been observed with some antibodies

• Cross-reactivity with mouse samples has been confirmed for specific antibodies like ab264191

• Some antibodies like ab244494 have been specifically validated for detecting endogenous BRF1 in human cell lines including MCF7 and SCLC-21H

When selecting a BRF1 antibody, researchers should consider the specific epitope recognized by the antibody, as different antibodies target different regions of the protein (e.g., aa 250-400, aa 550-600, or aa 600 to C-terminus) .

How should researchers optimize BRF1 antibody-based Western blotting protocols?

Optimizing Western blotting protocols for BRF1 detection requires attention to several key factors:

• Sample preparation:

  • Use appropriate lysis buffers that preserve BRF1 protein integrity

  • For cell lines like HeLa and 293T that express detectable levels of endogenous BRF1, load 5-50 μg of whole cell lysate

• Antibody concentration:

  • Primary antibody: Use at 0.04-0.4 μg/mL depending on the specific antibody and expected expression level

  • Secondary antibody: HRP-conjugated secondary antibodies should be diluted 1:50,000-100,000

• Detection considerations:

  • BRF1 has a predicted molecular weight of 74 kDa, but may appear at multiple bands (74, 140, and 200 kDa) depending on the antibody used

  • Different isoforms may be detected at different molecular weights

  • Use appropriate positive controls such as HeLa cell lysate which shows reliable BRF1 expression

• Optimization steps:

  • Test a range of antibody concentrations (titration) to determine optimal signal-to-noise ratio

  • Include blocking steps with 5% non-fat dry milk or BSA to reduce non-specific binding

  • Consider using enhanced chemiluminescence reagents from Cell Signaling Technology for optimal detection sensitivity

For example, when using ab74221, researchers successfully detected BRF1 in Western blot at 0.04 μg/mL concentration with HeLa whole cell lysate loaded at 5, 15, and 50 μg .

What are the critical parameters for successful immunohistochemical detection of BRF1?

Successful immunohistochemical detection of BRF1 requires optimization of several critical parameters:

• Fixation and tissue processing:

  • PFA fixation has been successfully used for immunofluorescence detection of BRF1 in MCF7 cells

  • For FFPE tissue sections, such as prostate carcinoma samples, standard formalin fixation protocols are effective

• Antigen retrieval:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is recommended

  • Optimization of retrieval time may be necessary depending on tissue type

• Antibody concentration and incubation:

  • For IHC-P, antibody concentrations should be carefully titrated

  • Extended incubation times (overnight at 4°C) may improve specific staining

• Detection system:

  • For brightfield microscopy, use HRP-conjugated secondary antibodies and DAB substrate

  • For fluorescence detection, use fluorophore-conjugated secondary antibodies

• Scoring and interpretation:

  • BRF1 staining can be evaluated based on both staining intensity and proportion of positively stained cells

  • Staining intensities can be scored as: 0 (no staining), 1 (weak/light yellow), 2 (moderate/yellow brown), or 3 (strong/brown)

  • Positive tumor cell proportion can be scored as: 0 (no positive cells), 1 (<5%), 2 (5-25%), 3 (25-50%), and 4 (>50%)

  • A staining index (SI) can be calculated by multiplying stain intensity by stain area

In breast cancer studies, BRF1 staining patterns have been categorized as negative staining (29.4%), weak nuclear staining (22.9%), moderate staining (19.3%), and strong staining (28.4%) .

How can researchers differentiate between BRF1 isoforms using antibodies?

Differentiating between BRF1 isoforms requires careful antibody selection and experimental design:

• Isoform-specific epitope targeting:

  • Select antibodies raised against epitopes unique to specific isoforms

  • Isoform 1 is involved in tRNA, VA1, 7SL and 5S RNA transcription

  • Isoform 2 is required for U6 promoter transcription

• Molecular weight discrimination:

  • Different isoforms may appear at distinct molecular weights on Western blots

  • Use appropriate molecular weight markers and positive controls to identify specific bands

  • Note that post-translational modifications may also affect apparent molecular weight

• Validation techniques:

  • Use isoform-specific siRNA knockdown to confirm antibody specificity

  • Employ recombinant expression of individual isoforms as positive controls

  • Consider using BRF1 knockout cells as negative controls

• Combined approaches:

  • Pair antibody-based detection with RT-PCR to correlate protein and mRNA isoform expression

  • Use phospho-specific antibodies when applicable, as isoforms may be differentially phosphorylated

• Subcellular localization:

  • Different isoforms may localize to distinct cellular compartments

  • Use cell fractionation followed by Western blotting or immunofluorescence to determine isoform-specific localization patterns

Researchers should be aware that currently available commercial antibodies may not specifically distinguish between all BRF1 isoforms, and additional validation may be required for isoform-specific studies.

What are the methodological considerations for immunoprecipitation of BRF1?

Successful immunoprecipitation (IP) of BRF1 requires attention to several methodological considerations:

• Antibody selection:

  • Use antibodies specifically validated for IP applications (e.g., ab264191, ab74221)

  • Consider using multiple antibodies targeting different epitopes for confirmation

• Protocol optimization:

  • Antibody concentration: 3 μg antibody per mg of lysate has been successfully used

  • Cell lysis: Use buffers that preserve protein-protein interactions if studying BRF1 complexes

  • Pre-clearing: Include pre-clearing steps with control IgG to reduce non-specific binding

• Controls:

  • Include negative control IPs with non-specific IgG of the same species and isotype

  • Use positive control IPs with known BRF1-interacting proteins

  • For validation, compare results with alternative BRF1 antibodies (e.g., ab264191 vs. ab74221)

• Detection methods:

  • Western blotting: Use 1 μg/ml antibody concentration for detection of immunoprecipitated BRF1

  • Consider mass spectrometry for unbiased identification of BRF1-interacting partners

• Applications:

  • Co-IP can be used to study BRF1 interaction with ERα in breast cancer cells

  • RNA-IP can identify mRNAs bound by BRF1, as demonstrated in studies of pluripotency regulation

For example, research has demonstrated successful BRF1 immunoprecipitation from 1 mg of HeLa whole cell lysate using ab264191 at 3 μg/mg lysate, with subsequent detection by Western blotting at 1 μg/ml .

How does BRF1 expression correlate with cancer progression and patient outcomes?

BRF1 expression shows significant correlations with cancer progression and patient outcomes, particularly in breast cancer:

• Expression patterns in cancer:

  • BRF1 is overexpressed in most cases of human breast cancer (HBC)

  • Strong BRF1 signals are observed in tumor foci compared to para-tissue (tissue around tumor foci)

  • In 218 cases of HBC, BRF1 expression showed: negative staining (29.4%), weak nuclear staining (22.9%), moderate staining (19.3%), and strong staining (28.4%)

• Association with clinical parameters:

  • BRF1 overexpression is associated with estrogen receptor-positive (ER+) status in breast cancer

  • Patients with high BRF1 expression have significantly longer survival periods than those with low BRF1 levels after hormone treatment

• Molecular mechanisms:

  • BRF1 and ERα are colocalized in the nucleus and interact with each other

  • This interaction synergistically regulates the transcription of Pol III genes

  • Inhibition of ERα by siRNA or tamoxifen reduces cellular levels of BRF1 and Pol III gene expression

• Potential as biomarker:

  • BRF1 has been identified as a promising biomarker for both diagnosis and prognosis of HBC

  • The interaction between BRF1 and ERα, as well as BRF1 itself, represent potential therapeutic targets

• Mechanistic relationship with cell transformation:

  • Upregulation of Pol III genes enhances tRNA and 5S RNA production

  • This increases the translational capacity of cells to promote cell transformation and tumor development

  • RNA polymerase III is overexpressed in many transformed cell lines and tumors in vivo

These findings suggest that BRF1 antibodies can be valuable tools for cancer research, particularly in studying the relationship between transcriptional regulation and cancer progression.

What techniques can be used to study BRF1's role in stem cell pluripotency regulation?

Studying BRF1's role in stem cell pluripotency regulation requires a combination of molecular and cellular techniques:

• Expression manipulation approaches:

  • siRNA knockdown: Can achieve approximately fourfold decrease in BRF1 protein levels

  • Transgene-mediated overexpression: Can increase BRF1 protein levels approximately fourfold above wild-type levels

  • These approaches have been used to study BRF1's effects on embryonic stem cell self-renewal and differentiation

• RNA immunoprecipitation sequencing (RIPseq):

  • Has been successfully employed to selectively enrich mRNAs bound by BRF1

  • Requires affinity-purified polyclonal antibody against BRF1

  • Allows identification of pluripotency-associated mRNAs bound by BRF1, such as Nanog

• Protein-RNA binding assays:

  • Direct binding of BRF1 to enriched mRNAs can be assessed using protein pull-down assays with RNA as bait

  • This approach has confirmed BRF1 binding to Nanog mRNA

• Signal pathway analysis:

  • Western blotting can detect changes in BRF1 protein levels in response to FGF/Erk MAP kinase signaling

  • Inhibitor treatment can reduce BRF1 levels by approximately 50% within 1.5 hours

• Differentiation assays:

  • BRF1 effects on differentiation can be assessed by measuring expression of lineage markers

  • In mESCs, BRF1 overexpression strongly affects upregulation of differentiation markers after LIF withdrawal

  • Flow cytometry can be used to profile expression of differentiation markers like Brachyury in BRF1-manipulated cells

• Co-culture experiments:

  • YFP(+) BRF1-overexpressing cells can be co-cultured with wild-type cells to quantify changes in self-renewal capacity

  • This approach revealed that BRF1 overexpression enhances commitment to mesendodermal fates, with markers like Brachyury showing up to 100-fold greater expression

These methods, combined with BRF1 antibodies for detection and isolation, provide powerful tools for understanding BRF1's role in stem cell biology.

How can researchers investigate BRF1 involvement in RNA polymerase III transcription regulation?

Investigating BRF1's role in RNA polymerase III transcription regulation requires specialized methodological approaches:

• Chromatin immunoprecipitation (ChIP):

  • Use BRF1 antibodies to immunoprecipitate BRF1-bound chromatin

  • Analyze binding to Pol III promoters (tRNA, 5S rRNA, etc.)

  • Compare occupancy at different promoter types (type 1, 2, and 3 Pol III promoters)

• Transcriptional reporter assays:

  • Employ luciferase reporters driven by Pol III promoters

  • Test effects of BRF1 overexpression or knockdown on reporter activity

  • Use promoter mutations to identify BRF1-responsive elements

• RNA analysis techniques:

  • Quantify Pol III transcripts (tRNA, 5S rRNA, 7SL RNA, U6 snRNA) using RT-qPCR

  • Northern blotting for direct visualization of Pol III transcript levels

  • RNA-seq with specific protocols optimized for small RNAs to capture Pol III transcripts

• Protein complex analysis:

  • Co-immunoprecipitation to identify BRF1 interactions with other TFIIIB components (TBP, TFIIIB)

  • Mass spectrometry to characterize BRF1-containing complexes at different promoters

  • Size exclusion chromatography to separate distinct BRF1-containing complexes

• Functional studies in cancer models:

  • Analyze correlation between BRF1 expression and Pol III activity in cancer cells

  • Study effects of tumor suppressors (RB, p53) on BRF1 function, as these proteins can bind and inactivate TFIIIB

  • Assess impact of ERα signaling on BRF1-mediated Pol III transcription in breast cancer models

• Isoform-specific analysis:

  • Compare functions of BRF1 isoform 1 (involved in tRNA, VA1, 7SL and 5S RNA transcription) and isoform 2 (required for U6 promoter transcription)

  • Use isoform-specific antibodies or tagged constructs to distinguish roles at different promoters

These approaches enable comprehensive investigation of BRF1's regulatory roles in RNA polymerase III transcription, which is critical for understanding cellular growth control and transformation.

What technical challenges might researchers encounter when using BRF1 antibodies and how can they be addressed?

Researchers working with BRF1 antibodies may encounter several technical challenges that require specific troubleshooting approaches:

• Multiple band detection in Western blotting:

  • Challenge: BRF1 antibodies may detect multiple bands at 74 kDa (predicted size), 140 kDa, and 200 kDa

  • Solution: Validate specificity using siRNA knockdown; include positive controls; consider phosphorylation states and isoforms

• Cross-reactivity issues:

  • Challenge: Some antibodies may cross-react with related proteins (e.g., BRF2)

  • Solution: Use antibodies with validated specificity; confirm results with multiple antibodies targeting different epitopes; include appropriate negative controls

• Variability in immunohistochemical staining:

  • Challenge: Inconsistent staining patterns across different tissues and fixation methods

  • Solution: Optimize antigen retrieval conditions; titrate antibody concentration; standardize scoring systems (using intensity and proportion scales as described in literature)

• Epitope masking in protein complexes:

  • Challenge: BRF1 epitopes may be masked when in complex with other proteins (e.g., ERα, TFIIIB components)

  • Solution: Try multiple antibodies targeting different epitopes; optimize fixation and extraction conditions; consider native vs. denaturing conditions

• Low endogenous expression levels:

  • Challenge: BRF1 may be expressed at low levels in some cell types

  • Solution: Increase protein loading; use more sensitive detection methods; consider enrichment by immunoprecipitation before detection

• Species cross-reactivity limitations:

  • Challenge: Not all BRF1 antibodies work across multiple species

  • Solution: Select antibodies with validated cross-reactivity; check sequence homology between species; perform validation in the species of interest

• Batch-to-batch variability:

  • Challenge: Performance may vary between antibody lots

  • Solution: Request lot-specific validation data; maintain reference samples; consider monoclonal antibodies for greater consistency

• Quantification difficulties:

  • Challenge: Standardizing BRF1 expression levels across samples and experiments

  • Solution: Use internal loading controls; include standard curves; employ digital image analysis for IHC quantification; consider using the staining index (SI) calculation method

Addressing these challenges through careful experimental design and validation will enhance the reliability and reproducibility of BRF1 antibody-based studies.

How can researchers study the interaction between BRF1 and estrogen receptor alpha (ERα) in breast cancer?

Investigating the interaction between BRF1 and ERα in breast cancer requires multiple complementary approaches:

• Co-localization studies:

  • Use dual immunofluorescence staining with antibodies against BRF1 and ERα

  • Analyze nuclear co-localization using confocal microscopy

  • Quantify co-localization using appropriate software and statistical analysis

  • Research has demonstrated that BRF1 and ERα are co-localized in the nucleus of breast cancer cells

• Co-immunoprecipitation (Co-IP):

  • Immunoprecipitate BRF1 using validated antibodies (e.g., ab264191, ab74221) and detect ERα in the precipitate

  • Perform reciprocal Co-IP by immunoprecipitating ERα and detecting BRF1

  • Include appropriate controls (non-specific IgG, input samples)

  • This approach has confirmed physical interaction between BRF1 and ERα proteins

• Chromatin immunoprecipitation (ChIP):

  • Use ChIP to analyze co-occupancy of BRF1 and ERα at specific genomic loci

  • Perform sequential ChIP (Re-ChIP) to confirm simultaneous binding

  • Analyze binding to Pol III gene promoters to understand their synergistic regulation

• Functional studies:

  • Manipulate ERα expression or activity using siRNA or inhibitors (e.g., tamoxifen)

  • Measure effects on BRF1 expression, localization, and function

  • Research has shown that inhibition of ERα by siRNA or tamoxifen reduces cellular levels of BRF1 and Pol III gene expression

• Clinical correlation studies:

  • Analyze BRF1 and ERα expression in breast cancer patient samples

  • Correlate expression with clinical parameters and outcome data

  • Studies have found that BRF1 overexpression is associated with ER-positive status, and patients with high BRF1 expression have longer survival periods after hormone treatment

• Mechanistic investigations:

  • Study how BRF1-ERα interaction affects RNA Pol III transcription

  • Investigate downstream effects on protein synthesis and cell growth

  • Examine the impact of this interaction on response to hormone therapy

  • Research has demonstrated that BRF1 and ERα synergistically regulate the transcription of Pol III genes

These approaches provide complementary data to understand the molecular basis and clinical significance of BRF1-ERα interaction in breast cancer.

What are the considerations for using BRF1 antibodies in studying stem cell differentiation pathways?

When using BRF1 antibodies to study stem cell differentiation pathways, researchers should consider several key factors:

• Temporal expression dynamics:

  • BRF1 expression changes rapidly in response to differentiation signals

  • Protein levels can decrease by approximately 50% within 1.5 hours of FGF/Erk MAP kinase signaling inhibition

  • Design time-course experiments to capture these dynamic changes

• Pathway-specific effects:

  • BRF1 has differential effects on specific differentiation lineages

  • It strongly enhances mesendodermal differentiation (100-fold increase in Brachyury expression)

  • It has minimal effect on neural differentiation in N2B27 serum-free media

  • Select appropriate differentiation conditions and markers for the pathway of interest

• Antibody selection for specific applications:

  • For detecting changes in endogenous BRF1 levels during differentiation: Western blotting

  • For analyzing BRF1 localization changes: Immunofluorescence

  • For identifying BRF1-bound mRNAs during differentiation: RNA immunoprecipitation

• Target validation approaches:

  • Compare BRF1 knockdown and overexpression phenotypes

  • Use multiple antibodies targeting different epitopes

  • Include rescue experiments to confirm specificity of observed effects

• Analysis of BRF1 targets:

  • BRF1 binds AU-rich sequences in many pluripotency-associated mRNAs

  • It can regulate the localization and abundance of key pluripotency factors like Nanog

  • Consider analyzing both direct transcriptional targets and post-transcriptional mRNA targets

• Experimental systems:

  • Mouse embryonic stem cells (mESCs) have been successfully used to study BRF1 function

  • Transgenic systems expressing H2B-YFP or Brf1-T2A-H2B-YFP allow tracking of BRF1-expressing cells

  • Consider co-culture experiments to assess competitive advantages/disadvantages of cells with altered BRF1 expression

• Marker selection for differentiation analysis:

  • For mesendodermal differentiation: Brachyury (T), Goosecoid (Gsc), Mixl1, and Wnt3A

  • For ectodermal differentiation: Nodal, Fgf5, and Gbx

  • For extraembryonic and definitive endoderm: Gata6, Hnf4a, and FoxA2

  • For neural differentiation: Sox1

These considerations will help researchers effectively use BRF1 antibodies to uncover the complex roles of BRF1 in stem cell differentiation decisions.

What methods can researchers use to validate the specificity of BRF1 antibodies?

Validating BRF1 antibody specificity is crucial for obtaining reliable experimental results. Researchers should employ multiple complementary approaches:

• Genetic knockdown/knockout validation:

  • Use siRNA knockdown to reduce BRF1 expression and confirm corresponding reduction in antibody signal

  • Studies have shown an approximately fourfold decrease in BRF1 protein relative to wild type using siRNA approaches

  • For definitive validation, use CRISPR/Cas9 knockout cells as negative controls

• Overexpression validation:

  • Test antibody specificity using BRF1 overexpression systems

  • Transgene-mediated overexpression achieving approximately fourfold increase in BRF1 protein levels has been reported

  • Use tagged BRF1 constructs to confirm co-localization with antibody signal

• Peptide competition assays:

  • Pre-incubate antibody with the immunizing peptide or recombinant BRF1 protein

  • This should abolish specific binding in subsequent applications

  • Particularly useful for polyclonal antibodies raised against synthetic peptides

• Multiple antibody comparison:

  • Use different antibodies targeting distinct epitopes of BRF1 (e.g., aa 250-400, aa 550-600, or aa 600 to C-terminus)

  • Compare staining patterns and band profiles across different antibodies

  • Concordant results from multiple antibodies increase confidence in specificity

• Cross-species reactivity testing:

  • Test antibody performance in multiple species with known BRF1 homology

  • Some antibodies are validated for both human and mouse samples

  • Lack of signal in species with low homology can support specificity

• Multiple application validation:

  • Confirm antibody specificity across different applications (WB, IP, ICC/IF, IHC-P)

  • Consistent results across applications provide stronger evidence of specificity

  • For example, ab264191 has been validated for IP, WB, and IHC-P applications

• Molecular weight verification:

  • Confirm that detected bands match predicted molecular weights

  • BRF1 has a predicted band size of 74 kDa, although additional bands at 140 kDa and 200 kDa may be observed

  • Use recombinant BRF1 protein as a positive control for size verification

• Mass spectrometry validation:

  • Immunoprecipitate BRF1 and analyze by mass spectrometry to confirm identity

  • This provides unbiased confirmation of antibody target specificity

These validation approaches should be documented and reported in publications to enhance reproducibility and confidence in research findings.

How can researchers optimize BRF1 antibody-based experiments in challenging sample types?

Optimizing BRF1 antibody-based experiments in challenging sample types requires specific strategies:

• Formalin-fixed paraffin-embedded (FFPE) tissues:

  • Optimize antigen retrieval: Test both citrate (pH 6.0) and EDTA (pH 9.0) buffers with varying retrieval times

  • Signal amplification: Consider tyramide signal amplification (TSA) or polymer-based detection systems

  • Background reduction: Use specific blocking solutions (e.g., animal serum matching secondary antibody host)

  • BRF1 antibodies have been successfully used in FFPE human prostate carcinoma and breast cancer samples

• Samples with low BRF1 expression:

  • Increase antibody concentration: Use higher concentrations while monitoring background

  • Extended incubation: Increase primary antibody incubation time (overnight at 4°C)

  • Sample enrichment: Consider IP-Western approach to concentrate BRF1 before detection

  • Signal enhancement: Use more sensitive detection systems (ECL Prime, SuperSignal West Femto)

• High background samples:

  • Pre-adsorption: Pre-adsorb antibodies against tissues lacking BRF1 expression

  • Optimize blocking: Test different blocking agents (BSA, normal serum, commercial blockers)

  • Increase washing: Use additional and longer washing steps with 0.1% Tween-20

  • Titrate antibody: Test serial dilutions to find optimal signal-to-noise ratio

  • For immunofluorescence, use Sudan Black to reduce autofluorescence

• Degraded samples:

  • Target epitope selection: Choose antibodies targeting stable protein regions

  • Sample processing: Minimize delay between collection and fixation

  • Protease inhibitors: Include in all extraction buffers

  • Antibody cocktails: Use multiple antibodies targeting different epitopes

• Small samples (biopsies):

  • Signal amplification: Use biotin-streptavidin systems or polymer-based detection

  • Optimize section thickness: Use thicker sections (5-7 μm) for greater antigen availability

  • Whole slide imaging: Use digital pathology for comprehensive analysis of limited material

  • Multiplexing: Consider sequential or simultaneous detection of multiple markers

• Research-specific optimizations:

  • For breast cancer tissue: Optimize scoring methods using both staining intensity and proportion metrics

  • For stem cell studies: Optimize fixation to preserve both BRF1 and pluripotency marker detection

  • For RNA-protein interaction studies: Use specialized crosslinking methods to preserve RNA-protein complexes for RNA-IP

These optimizations should be systematically tested and documented to establish robust protocols for challenging sample types.

What are the advanced applications of BRF1 antibodies in studying RNA regulation mechanisms?

BRF1 antibodies enable several advanced applications for investigating RNA regulation mechanisms:

• RNA immunoprecipitation sequencing (RIPseq):

  • BRF1 antibodies can selectively enrich mRNAs bound by BRF1

  • This technique has identified pluripotency-associated mRNAs bound by BRF1, including Nanog

  • Quantitative enrichment can be calculated to identify high-confidence BRF1 targets

  • Protocol considerations: Use affinity-purified polyclonal antibodies; include non-specific IgG controls

• Cross-linking immunoprecipitation (CLIP):

  • More stringent than standard RIP for identifying direct RNA-protein interactions

  • UV crosslinking preserves direct RNA-protein contacts for BRF1

  • Various CLIP variants (PAR-CLIP, iCLIP, eCLIP) can provide single-nucleotide resolution of binding sites

  • Can identify the specific AU-rich sequences bound by BRF1 in target mRNAs

• Proximity-dependent biotin identification (BioID):

  • Fusion of BRF1 with a biotin ligase enables identification of proximal proteins

  • Useful for mapping the BRF1 interactome in different cellular contexts

  • Can identify novel proteins involved in BRF1-mediated RNA regulation

• Live-cell imaging of RNA regulation:

  • Combine BRF1 antibodies or tagged BRF1 with RNA visualization techniques

  • MS2-GFP system can track BRF1 target mRNAs in living cells

  • TRICK (translating RNA imaging by coat protein knock-off) can monitor translation of BRF1-regulated mRNAs

• Ribosome profiling with BRF1 perturbation:

  • Analyze how BRF1 knockdown or overexpression affects translation efficiency

  • Can identify mRNAs whose translation is regulated by BRF1

  • Important for understanding how BRF1 connects transcriptional and translational regulation

• Chromatin immunoprecipitation followed by sequencing (ChIP-seq):

  • Maps genome-wide binding sites of BRF1 at RNA polymerase III-transcribed genes

  • Can identify differences in binding patterns between cell types or conditions

  • ChIP-seq has revealed BRF1 binding to tRNA genes, 5S rRNA genes, and other Pol III targets

• Single-cell analysis of BRF1 function:

  • Combine BRF1 antibodies with single-cell techniques

  • Single-cell Western blotting can detect BRF1 variations in individual cells

  • CyTOF (mass cytometry) can measure BRF1 alongside multiple other proteins

These advanced applications leverage BRF1 antibodies to provide mechanistic insights into RNA regulation at transcriptional and post-transcriptional levels.

How do different experimental conditions affect BRF1 antibody performance?

Experimental conditions significantly impact BRF1 antibody performance across different applications:

• Fixation effects in immunocytochemistry/immunohistochemistry:

  • PFA fixation (4%) has been successfully used for BRF1 detection in MCF7 cells

  • Triton X-100 (0.1%) permeabilization enables adequate antibody access to nuclear BRF1

  • Over-fixation can mask epitopes and reduce signal intensity

  • Different fixatives may alter BRF1 epitope accessibility differently; optimization is recommended

• Buffer composition for Western blotting:

  • Lysis buffer selection affects protein extraction efficiency

  • RIPA buffer is commonly used but may disrupt some protein-protein interactions

  • NP-40 or Triton X-100 based buffers may better preserve BRF1 complexes

  • Include phosphatase inhibitors to preserve phosphorylation states that may affect antibody recognition

• Temperature and time considerations:

  • Primary antibody incubation at 4°C overnight often yields better results than shorter incubations at room temperature

  • Antigen retrieval temperature and duration significantly impact epitope exposure in FFPE tissues

  • SDS-PAGE running conditions can affect band resolution and apparent molecular weight

• pH sensitivity:

  • Antigen retrieval solutions at different pH values (citrate pH 6.0 vs. EDTA pH 9.0) may yield different results

  • Transfer buffer pH can impact efficiency of protein transfer to membranes

  • Washing buffer pH affects antibody-antigen interaction stability

• Blocking agent selection:

  • Milk-based blockers may contain phosphatases that could affect phospho-epitopes

  • BSA may be preferred for phospho-specific detection

  • Commercial blocking reagents may provide more consistent results across experiments

• Detection system optimization:

  • ECL substrates of different sensitivities may be required depending on BRF1 expression levels

  • Fluorescent secondary antibodies enable multiplex detection and wider dynamic range

  • Tyramide signal amplification can enhance sensitivity for low abundance detection

• Sample storage effects:

  • Freeze-thaw cycles can degrade BRF1 protein and reduce antibody signal

  • Long-term storage of FFPE blocks or slides may reduce antigenicity

  • Protein extracts should be aliquoted and stored at -80°C with protease inhibitors

• Antibody dilution optimization:

  • Optimal dilutions vary by application: 0.04-0.4 μg/mL for WB, 0.25-2 μg/mL for ICC/IF

  • Titration experiments are essential to determine optimal concentration for each new lot and application

  • Higher concentrations may be needed for less abundant targets or challenging sample types